Skip to content

Study · Case report or series · n = 2 · 2026

4 results

Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.

Schwarz CR, Vilsbøll T, Aistrup MØ, Kloppenborg JT

Pediatrics1 Jun 2026

PMID42097623 (opens in a new tab)DOI10.1542/peds.2025-074286 (opens in a new tab)PepBankPUB-42097623
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In two adolescents with type 1 diabetes and obesity on insulin pumps, adding semaglutide for 12 months was followed by improved glycemic control.

    In plain wordsIn two adolescents with type 1 diabetes and obesity, blood sugar control improved after 12 months of added semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycemic control
    Study

    n = 2

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Both adolescents achieved notable improvements in glycemic control, weight, and insulin requirement after 12 months of treatment without any adverse events.
    2 context sentences
    Summary · context
    Two female individuals (17 and 12 years old) with T1D who have automated and continuous insulin delivery systems presented with marked weight gain, increasing insulin requirement, and suboptimal glycemic control.
    Summary · context
    We added GLP-1RA to standard insulin pump therapy and revisited education related to healthy lifestyle.
  2. 02HumanCase report or seriesEfficacy outcome

    In two adolescents with type 1 diabetes and obesity on insulin pumps, adding semaglutide for 12 months was followed by improved weight.

    In plain wordsIn two adolescents with type 1 diabetes and obesity, weight improved after 12 months of added semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 2

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Both adolescents achieved notable improvements in glycemic control, weight, and insulin requirement after 12 months of treatment without any adverse events.
    2 context sentences
    Summary · context
    Two female individuals (17 and 12 years old) with T1D who have automated and continuous insulin delivery systems presented with marked weight gain, increasing insulin requirement, and suboptimal glycemic control.
    Summary · context
    We added GLP-1RA to standard insulin pump therapy and revisited education related to healthy lifestyle.
  3. 03HumanCase report or seriesEfficacy outcome

    In two adolescents with type 1 diabetes and obesity on insulin pumps, adding semaglutide for 12 months was followed by improved insulin requirement.

    In plain wordsIn two adolescents with type 1 diabetes and obesity, insulin needs improved after 12 months of added semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin requirement
    Study

    n = 2

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Both adolescents achieved notable improvements in glycemic control, weight, and insulin requirement after 12 months of treatment without any adverse events.
    2 context sentences
    Summary · context
    Two female individuals (17 and 12 years old) with T1D who have automated and continuous insulin delivery systems presented with marked weight gain, increasing insulin requirement, and suboptimal glycemic control.
    Summary · context
    We added GLP-1RA to standard insulin pump therapy and revisited education related to healthy lifestyle.
  4. 04HumanCase report or seriesSafety outcome

    In two adolescents with type 1 diabetes and obesity, no adverse events were reported during 12 months of semaglutide.

    In plain wordsIn two adolescents with type 1 diabetes and obesity, no side effects were reported over 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse events
    Study

    n = 2

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    without any adverse events.
    2 context sentences
    Summary · context
    Two female individuals (17 and 12 years old) with T1D who have automated and continuous insulin delivery systems presented with marked weight gain, increasing insulin requirement, and suboptimal glycemic control.
    Summary · context
    We added GLP-1RA to standard insulin pump therapy and revisited education related to healthy lifestyle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.